NEW YORK, Jan. 14-Eli Lilly Canada will work with MDS Proteomics to evaluate PhosMap, an MDS technology that characterizes the changes in proteins that may develop during drug therapy.
Lilly will use the technology to assess the effects of kinase inhibitors on kinase targets. The collaboration is designed as a demonstration of the system.
Financial terms of the collaboration were not revealed. For further details, see the company website.
Eli Lilly Canada, headquartered in Toronto, is a division of Eli Lilly.
MDS Proteomics is a subsidiary of MDS.